CD19 Targeted Chimeric Antigen Receptor T Cells for B Cell Lymphoma
NCT03118180
·
clinicaltrials.gov ↗
PHASE1,PHASE2
Phase
UNKNOWN
Status
50
Enrollment
OTHER
Sponsor class
Conditions
Lymphoma
Interventions
BIOLOGICAL:
CD19 targeted chimeric antigen receptor T cells
Sponsor
Zhejiang University
Collaborators
[object Object]